Cue Biopharma, Inc. entered into a Securities Purchase Agreement on July 9, 2026, to issue and sell 1,418,071 shares of common stock at $33.21 per share and 87,500 pre-funded warrants at $33.209 per warrant for gross proceeds of approximately $50.0 million. The company intends to use the net proceeds to fund clinical development and general corporate purposes. Cue Biopharma, Inc. is a biopharmaceutical company focused on developing clinical-stage product candidates.